- Merck KGaA
- 28 April 2025 16:29:02
Source: Sharecast
Merck is paying $47 per share for SpringWorks, representing an equity value of $3.9bn. While only a slight premium to SpringWork's closing price of $44.72 on Friday, the shares have surged by around 20% over the past five trading sessions.
SpringWorks provides therapy to adults with desmoid tumours, with an approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas.
Merck said the deal is fully aligned with its strategy to pursue in-licensing of "high-quality compounds at various stages of development and focused acquisitions that promise early value creation".
Belén Garijo, Merck's chair, said the acquisition represents a "major step in our active portfolio strategy to position Merck as a globally diversified, innovation and technology powerhouse".
Garijo continued: "For our Healthcare sector, it sharpens the focus on rare tumors, accelerates growth, and strengthens our presence in the US."
SpringWorks' share price was up 3.3% at $46.20 by 1127 in New York, while Merck gained 0.7% to $83.33 in Frankfurt.